Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 plus Glucocorticoids in Newly Diagnosed ITP
NCT06992128Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of romiplostim in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of patients with continuous remission at 6 months. Started May 2025; status: recruiting.
02
Drugs
romiplostim
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06992128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992128.